January 28, 2021 -- Bio-Techne has made an initial minority strategic equity investment in Changzhou Eminence Biotechnology (Eminence). The companies will synergistically work on the development and commercialization of good manufacturing practice (GMP) molecules and proteins for cell and gene therapy media.
Eminence will use the funds to expand its manufacturing capacity and increase the service capabilities of its China-headquartered GMP media production facility. Eminence will leverage Bio-Techne's industry-wide recognition as a high-quality supplier to the life sciences industry and its existing relationships with biopharmaceutical companies.
Founded in 2016, Eminence is focused on supplying life science companies with media, including Chinese hamster ovary (CHO) cells and other serum-free media products, as well as custom cell line and media formulation development services. The company is in the process of completing and scaling its GMP production facility, which is expected to be finished by the end of 2021.